Dr. Reck on Updated Results of the CheckMate 9LA Trial in Advanced NSCLC
Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.
Dr. Reck on the Efficacy of Maintenance Atezolizumab in ES-SCLC
Martin Reck, MD, PhD, discusses the efficacy of maintenance atezolizumab in patients with extensive-stage small cell lung cancer.
Dr. Reck on the Safety of Pembrolizumab in KEYNOTE-024 in Metastatic NSCLC
Martin Reck, MD, PhD, discusses the safety profile observed with of pembrolizumab versus chemotherapy in patients with metastatic non–small cell lung cancer in the phase 3 KEYNOTE-024 trial.
Dr. Reck on Safety Data From the CheckMate-9LA Trial in Metastatic/Recurrent NSCLC
Martin Reck, MD, PhD, discusses safety data from the phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.
Dr. Reck on the Rationale of the IMpower150 Trial in NSCLC
Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discusses the IMpower150 trial data for patients with non
Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC
Cabozantinib Plus Nivolumab/Ipilimumab Generates PFS and DCR in Metastatic Soft Tissue Sarcoma
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma
Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer
Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC
2 Clarke Drive Cranbury, NJ 08512